Literature DB >> 23255052

Sonic advance: CCN1 regulates sonic hedgehog in pancreatic cancer.

Andrew Leask1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fifth leading cause of cancer internationally. As the precise molecular pathways that regulate pancreatic cancer are incompletely understood, appropriate targets for drug intervention remain elusive. It is being increasingly appreciated that the cellular microenvironment plays an important role in driving tumor growth and metastasis. CCN1, a member of the CCN family of secreted matricellular proteins, is overexpressed in pancreatic cancer, and may represent a novel target for therapy. Sonic hedgehog (SHh) is responsible for PDAC cell proliferation, epithelial-mesenchymal transition (EMT), maintenance of cancer stemness, migration, invasion, and metastatic growth; in a recent report, it was shown that CCN1 is a potent regulator of SHh expression via Notch-1. CCN1 activity was mediated, at least in part, through altering proteosome activity. These results suggest that CCN1 may be an ideal target for treating PDAC.

Entities:  

Year:  2012        PMID: 23255052      PMCID: PMC3590359          DOI: 10.1007/s12079-012-0187-x

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  14 in total

1.  Meeting report: novel targets for cancer and connective tissues diseases.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-11-15       Impact factor: 5.782

Review 2.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 3.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

4.  CCN1: a novel target for pancreatic cancer.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-04-05       Impact factor: 5.782

5.  Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

Authors:  Eleni Maniati; Maud Bossard; Natalie Cook; Juliana B Candido; Nia Emami-Shahri; Sergei A Nedospasov; Frances R Balkwill; David A Tuveson; Thorsten Hagemann
Journal:  J Clin Invest       Date:  2011-11-07       Impact factor: 14.808

6.  Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.

Authors:  Michael Jewer; Scott D Findlay; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2012-10-09       Impact factor: 5.782

7.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

8.  Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models.

Authors:  Keane K Y Lai; Sufen Shang; Neha Lohia; Garrett C Booth; Derek J Masse; Nelson Fausto; Jean S Campbell; Laura Beretta
Journal:  PLoS Genet       Date:  2011-06-23       Impact factor: 5.917

9.  Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis.

Authors:  Inamul Haque; Smita Mehta; Monami Majumder; Kakali Dhar; Archana De; Douglas McGregor; Peter J Van Veldhuizen; Sushanta K Banerjee; Snigdha Banerjee
Journal:  Mol Cancer       Date:  2011-01-13       Impact factor: 27.401

10.  Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.

Authors:  Kevin Vo; Barushi Amarasinghe; Kay Washington; Adriana Gonzalez; Jordan Berlin; Thao P Dang
Journal:  Mol Cancer       Date:  2011-11-10       Impact factor: 27.401

View more
  7 in total

Review 1.  Protein PEGylation for cancer therapy: bench to bedside.

Authors:  Vijayalaxmi Gupta; Sneha Bhavanasi; Mohiuddin Quadir; Kevin Singh; Gaurav Ghosh; Kritin Vasamreddy; Arnab Ghosh; Teruna J Siahaan; Snigdha Banerjee; Sushanta K Banerjee
Journal:  J Cell Commun Signal       Date:  2018-11-29       Impact factor: 5.782

Review 2.  Role of Notch signaling pathway in pancreatic cancer.

Authors:  Jiankun Gao; Bo Long; Zhiwei Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 3.  Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1.

Authors:  Alex Giakoustidis; Dimitrios Giakoustidis; Satvinder Mudan; Argyrios Sklavos; Roger Williams
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

4.  CCN1 (CYR61) and CCN3 (NOV) signaling drives human trophoblast cells into senescence and stimulates migration properties.

Authors:  Friederike Kipkeew; Manuela Kirsch; Diana Klein; Manuela Wuelling; Elke Winterhager; Alexandra Gellhaus
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

5.  Human pancreatic cancer progression: an anarchy among CCN-siblings.

Authors:  Sushanta K Banerjee; Gargi Maity; Inamul Haque; Arnab Ghosh; Sandipto Sarkar; Vijayalaxmi Gupta; Donald R Campbell; Daniel Von Hoff; Snigdha Banerjee
Journal:  J Cell Commun Signal       Date:  2016-08-19       Impact factor: 5.782

6.  The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.

Authors:  Gargi Maity; Inamul Haque; Arnab Ghosh; Gopal Dhar; Vijayalaxmi Gupta; Sandipto Sarkar; Imaan Azeem; Douglas McGregor; Abhishek Choudhary; Donald R Campbell; Suman Kambhampati; Sushanta K Banerjee; Snigdha Banerjee
Journal:  J Biol Chem       Date:  2018-02-06       Impact factor: 5.157

7.  Pancreatic tumor cell secreted CCN1/Cyr61 promotes endothelial cell migration and aberrant neovascularization.

Authors:  Gargi Maity; Smita Mehta; Inamul Haque; Kakali Dhar; Sandipto Sarkar; Sushanta K Banerjee; Snigdha Banerjee
Journal:  Sci Rep       Date:  2014-05-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.